Efficacy and safety of a novel combined 1060-nm and 635-nm laser device for non-invasive reduction of abdominal and submental fat

2021 ◽  
Author(s):  
Ik Jun Moon ◽  
Jae Won Choi ◽  
Chang Jin Jung ◽  
SeokHwan Kim ◽  
EunSoo Park ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Laser Device ◽  
Non Invasive ◽  
Submental Fat

scholarly journals Clinical Research of Ultrasound Ciliary Plasty and Implications for Clinical Practice

2016 ◽  
Vol 10 (02) ◽  
pp. 108 ◽  
Author(s):  
Philippe Denis ◽  
Keyword(s):  
First Generation ◽  
Meta Analysis ◽  
Invasive Procedure ◽  
Common Side Effect ◽  
Efficacy And Safety ◽  
Refractory Glaucoma ◽  
Effective Treatment Option ◽  
Non Invasive ◽  
Surgical Failure ◽  
Conjunctival Bleb

Ultrasound ciliary plasty (UCP) is a novel, non-invasive procedure for the control of intraocular pressure (IOP) in patients with openangle glaucoma (OAG), and is particularly useful for refractory glaucoma after failed filtering surgery and patients with elevated risk of surgical failure due to high risk of conjunctival bleb scarring. A meta-analysis was performed of seven clinical trials, involving 251 patients, which evaluated the efficacy and safety of the procedure. The procedure was effective in reducing mean IOP across all indications and IOP reductions were similar in patients with refractory and non-refractory glaucoma. Safety and tolerability were good, with conjunctival hyperaemia being the most common side effect. Serious complications were rare. Procedures using the second-generation therapy probe were associated with superior reproducibility of IOP reduction compared with the first-generation probe. In summary, the procedure is a promising and effective treatment option for patients with refractory and non-refractory OAG.

scholarly journals Rationale and design for a randomized, single-center, double-blind, sham-controlled study of non-invasive vagus nerve stimulation for treatment of post-traumatic headache

Neurology ◽  
2019 ◽  
Vol 93 (14 Supplement 1) ◽  
pp. S1.1-S1
Author(s):  
Bert Vargas ◽  
Eric Liebler ◽  
Stephen Bunt ◽  
Charlene Supent-Bell
Keyword(s):  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Acute Treatment ◽  
Preventive Therapy ◽  
Efficacy And Safety ◽  
Headache Disorders ◽  
Double Blind ◽  
Non Invasive ◽  
Post Traumatic

ObjectiveEvaluate the efficacy and safety of non-invasive vagus nerve stimulation (nVNS) for the treatment of post-traumatic headache (PTH).BackgroundWorldwide, ∼69 million people per year sustain a traumatic brain injury (TBI), many of whom develop PTH. Clinicians often treat PTH with drugs approved for primary headache disorders, and many patients self-treat with over-the-counter agents but have inadequate pain relief. There has been little study of therapies for PTH, and safe, effective treatments are needed.Design/MethodsThis randomized, double-blind, sham-controlled, parallel-group pilot study is enrolling adults who present 1–4 weeks after a head injury, meet International Classification of Headache Disorders 3rd edition (ICHD-3) criteria for acute headache attributed to mild TBI, and have ≥2 headaches/week with a migraine or probable migraine phenotype. After a 2-week run-in period, subjects are randomly assigned (1:1 allocation) to receive daily preventive therapy and as-needed acute treatment with nVNS or a sham device. Preventive therapy consists of two 120-second stimulations 3 times daily. Acute treatment comprises 2 stimulations at headache onset and 2 stimulations 20 minutes after the start of initial treatment. Subjects are not to use acute rescue medication for 120 minutes post-treatment. One North American site will enroll ≤80 subjects. The expected duration is 12 months (enrollment, 9 months; participation, 14 weeks).ResultsThe primary effectiveness end point is decrease in pain (on a 7-point scale) 60 minutes post-treatment for all treated headache attacks. Secondary end points include decrease in the frequency of headache days between the run-in period and the last 2 weeks of the double-blind period and responder rates (ie, percentages of subjects with ≥50% decrease in attack frequency). The primary safety end point is the incidence of treatment-related serious adverse events.ConclusionsThis study will assess the efficacy and safety of nVNS as a novel therapy for PTH.

A Combined Triple-Wavelength (755nm, 810nm, and 1064nm) Laser Device for Hair Removal: Efficacy and Safety Study

2020 ◽  
Vol 19 (5) ◽  
pp. 515-518
Author(s):  
Akerman Lehavit ◽  
Galili Eran ◽  
Lapidoth Moshe ◽  
Levi Assi
Keyword(s):  
Hair Removal ◽  
Efficacy And Safety ◽  
Laser Device ◽  
Safety Study

scholarly journals Safety and efficacy of cryolipolysis for non‐invasive reduction of submental fat

2015 ◽  
Vol 48 (1) ◽  
pp. 3-13 ◽  
Author(s):  
Suzanne L. Kilmer ◽  
A. Jay Burns ◽  
Brian D. Zelickson
Keyword(s):  
Safety And Efficacy ◽  
Non Invasive ◽  
Submental Fat

scholarly journals The evaluation of the efficacy and safety of non-invasive neurally adjusted ventilatory assist in combination with INtubation-SURfactant-Extubation technique for infants at 28 to 33 weeks of gestation with respiratory distress syndrome

2019 ◽  
Vol 7 ◽  
pp. 205031211983841 ◽  
Author(s):  
Jun Miyahara ◽  
Hiroshi Sugiura ◽  
Shigeru Ohki
Keyword(s):  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Preterm Infants ◽  
Distress Syndrome ◽  
Periventricular Leukomalacia ◽  
Extubation Failure ◽  
Neurally Adjusted Ventilatory Assist ◽  
Efficacy And Safety ◽  
Non Invasive ◽  
Ventilatory Assist

Objectives: The aim of this study is to evaluate the efficacy and safety of non-invasive neurally adjusted ventilatory assist used after INtubation-SURfactant-Extubation in preterm infants with respiratory distress syndrome. Methods: We conducted a prospective observational study that included 15 inborn preterm infants at 28 (0/7) to 33 (6/7) weeks of gestation with respiratory distress syndrome in the period from April 2017 to October 2018. After INtubation-SURfactant-Extubation, infants underwent non-invasive neurally adjusted ventilatory assist. INtubation-SURfactant-Extubation failure was defined as follows: fraction of inspired oxygen requirement >0.4, respiratory acidosis, and severe apnea within 5 days after surfactant administration. Results: Two of the 15 (13.3%) infants showed INtubation-SURfactant-Extubation failure and required mechanical ventilation. No infants experienced any major complications such as pneumothorax, patent ductus arteriosus ligation, severe intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, or death. Conclusion: The rate of INtubation-SURfactant-Extubation failure when non-invasive neurally adjusted ventilatory assist was used after INtubation-SURfactant-Extubation for preterm infants with respiratory distress syndrome was 13.3%. Non-invasive neurally adjusted ventilatory assist can be safely performed without severe complications for preterm infants soon after birth.

Efficacy and safety of non-invasive body tightening with high-intensity focused ultrasound (HIFU)

2017 ◽  
Vol 23 (4) ◽  
pp. 558-562 ◽  
Author(s):  
E. J. Ko ◽  
J. Y. Hong ◽  
T.-R. Kwon ◽  
E. J. Choi ◽  
Y.-J. Jang ◽  
...  
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Efficacy And Safety ◽  
Non Invasive

scholarly journals Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (11) ◽  
pp. 2503
Author(s):  
Adrian V. Hernandez ◽  
Mi T. Phan ◽  
Jonathon Rocco ◽  
Vinay Pasupuleti ◽  
Joshuan J. Barboza ◽  
...  
Keyword(s):  
Adverse Events ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Non Invasive ◽  
Non Invasive Ventilation ◽  
Inverse Variance ◽  
Secondary Outcomes ◽  
Meta Analyses

We systematically reviewed the efficacy and safety of hydroxychloroquine as treatment for hospitalized COVID-19. Randomized controlled trials (RCTs) evaluating hydroxychloroquine as treatment for hospitalized COVID-19 patients were searched until 2nd of December 2020. Primary outcomes were all-cause mortality, need of mechanical ventilation, need of non-invasive ventilation, ICU admission and oxygen support at 14 and 30 days. Secondary outcomes were clinical recovery and worsening, discharge, radiological progression of pneumonia, virologic clearance, serious adverse events (SAE) and adverse events. Inverse variance random effects meta-analyses were performed. Thirteen RCTs (n=18,540) were included. Hydroxychloroquine total doses ranged between 2000 and 12,400 mg; treatment durations were from 5 to 16 days and follow up times between 5 and 30 days. Compared to controls, hydroxychloroquine non-significantly increased mortality at 14 days (RR 1.07, 95%CI 0.92–1.25) or 30 days (RR 1.08, 95%CI 1.00–1.16). Hydroxychloroquine did not affect other primary or secondary outcomes, except SAEs that were significantly higher than the control (RR 1.24, 95%CI 1.05–1.46). Eleven RCTs had high or some concerns of bias. Subgroup analyses were consistent with main analyses. Hydroxychloroquine was not efficacious for treating hospitalized COVID-19 patients and caused more severe adverse events. Hydroxychloroquine should not be recommended as treatment for hospitalized COVID-19 patients.

scholarly journals Self-administered acupressure for allergic rhinitis: Study protocol for a randomized controlled trial

2018 ◽  
Author(s):  
Yaqun Liang ◽  
George Binh Lenon ◽  
Angela Wei Hong Yang
Keyword(s):  
Allergic Rhinitis ◽  
Controlled Trial ◽  
Scientific Evidence ◽  
Trial Registration ◽  
Life Questionnaire ◽  
Efficacy And Safety ◽  
Non Invasive ◽  
Randomized Controlled ◽  
Ige Mediated ◽  
Clinical Trials Registry

Abstract Background: Allergic rhinitis (AR) is an IgE-mediated inflammatory disease. Current conventional therapies for AR are unsatisfactory. Acupuncture has been recommended as an optional treatment for AR patients who are interested in non-pharmacotherapy in the new clinical practice guidelines for AR. Acupressure is a sub-type of acupuncture which is non-invasive with a low risk and can be self-administered. However, the current limited evidence is compromised by the high risk of bias and heterogeneity of methodology. Therefore, rigorously designed randomized controlled trials (RCTs) are needed. This proposed RCT aims to evaluate the efficacy and safety of self-administered acupressure for the management of AR. Methods/design: We have designed a randomized, single blind, non-specific controlled, two-arm, parallel clinical trial involving a 2-week run-in period, a 4-week intervention period and an 8-week follow-up period. The eligible participants will be randomized into either specific or non-specific acupressure group. They will be required to perform self-administered acupressure on either 5 specific acupressure points or 5 non-specific acupressure points, one minute for each point, twice a day for 4 weeks. Participants will be asked to complete self-administered questionnaires for outcome measures including 7-point scale of symptom severity, Rhinoconjunctivitis Quality of Life Questionnaire with Standardized Activities (RQLQs), relief medication scores, adverse events and participants’ opinion of this study at the different assessment points throughout the trial period. Data will be analyzed by chi-square, t-test or ANOVA using Statistical Package for Social Science (SPSS) software. Discussion: The findings from this study will provide scientific evidence for the efficacy and safety of self-administered acupressure for the management of AR. This study may assist to develop a non-cost, non-invasive self-management method for AR sufferers. Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617001106325 (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373370). Registered on 28 July 2017. Keywords: Hay fever; allergic disease; acupuncture; self-massage; evidence-based Chinese medicine.

Sign in / Sign up

Export Citation Format

Share Document